Survival of patients with MRC intermediate-risk cytogenetics according to the combined NPM1 and FLT3-ITD mutations status and DNMT3A and RUNX1 mutations. (A) OS of MRC intermediate-risk patients aged <60 years or (B) aged ≥60 years, stratified according to the combined NPM1/FLT3-ITD genotype and DNMT3A mutations status. (C) OS of MRC intermediate-risk patients aged <60 years or (D) aged ≥60 years, comparing patients with mutated RUNX1 to RUNX1–wild-type patients with mutated NPM1 without FLT3-ITD (this prognostically favorable genotype was mutually exclusive with mutated RUNX1, and is thus shown separately), and all remaining patients (ie, wild-type NPM1 and/or FLT3-ITD and wild-type RUNX1). P values were calculated from bivariate Cox proportional hazards models stratified for trial arm, using the Wald test. mut, mutated; neg, negative; wt, wild-type.